期刊文献+

ⅠA期乳腺癌临床病理特征、中医证型及预后相关因素分析 被引量:8

Analysis of clinicopathological characteristics and syndromes of traditional Chinese medicine and prognostic factors in breast cancer patients of stageⅠA
下载PDF
导出
摘要 [目的]探讨156例ⅠA期乳腺癌患者的临床病理特征、中医证型、治疗与预后的关系。[方法]收集2004年1月—2009年12月天津医科大学肿瘤医院收治的156例早期乳腺癌(T_1N_0M_0,ⅠA期)的临床病理资料进行回顾性分析。[结果]患者病理类型以浸润性导管癌为主;中医辨证临床可分为肝气郁结证、冲任失调证、燥毒蕴结证及气血双亏兼邪毒内陷证4型,以肝气郁结证为主;原发肿瘤大小以T1c居多;组织学分级以Ⅱ级及Ⅲ级为主。5 a PFS为93.3%,5 a OS为99.1%。单因素分析结果显示,组织学分级、Ki-67表达及淋巴脉管侵犯与患者的PFS相关;多因素分析显示,组织学分级及Ki-67表达情况是影响ⅠA期(T_1N_0M_0)乳腺癌患者PFS的独立预后因素。[结论]ⅠA期(T_1N_0M_0)乳腺癌患者虽然总体预后较好,但某些亚组患者预后较差,存在明显的复发转移风险。 [Objective] To investigate the relationship between clinicopathological characteristics, syndromes of traditional Chinese medicine (TCM), treatment and prognosis of 156 patients with breast cancer in stage IA. [Methods] Clinical and pathological data of 156 cases of early breast cancer (T1N0M0, I A) were collected and retrospectively analyzed from January 2004 to December 2009 in Tianjin Medical University Cancer Hospital. [Results] Infiltrate ductal carcinoma was the most common pathologic type; Syndrome differentiation of TCM can be divided into syndrome of stagnation of liver qi, disharmony syndrome, dryness toxin accumulation syndrome and Qi and blood deficiency and toxin depression syndrome type. Syndrome of stagnation of liver Qi was the most syndrome type; T1c was the most primary tumor size; Grade Ⅱ and Grade Ⅲ were the most histological grades. 5 year PFS was 93.3% and 5 year OS was 99.1%. PFS was related to histological grade and Ki-67 expression and lymphvascular invasion in univariate analysis; Multivariate analysis showed that histological grade and Ki-67 expression were independent prognostic factors for PFS in breast cancer patients with stage I A (T1N0M0). [Conclusion] Although the overall prognosis of breast cancer patients with stage I A (T1N0M0) is better, there was a significant risk of recurrence and metastases in patients in some subgroups who had a poor prognosis.
出处 《天津中医药大学学报》 CAS 2016年第4期225-229,共5页 Journal of Tianjin University of Traditional Chinese Medicine
基金 国家科技支撑计划项目(2005BAI12B15)
关键词 乳腺肿瘤 小肿瘤 临床病理特征 辨证分型 预后 breast neoplasms small tumor clinicopathological characteristics syndrome differentiation prognosis
  • 相关文献

参考文献16

  • 1Siegel R, Ma J, Zou Z, et al. Cancer statistics[J]. CA Cancer J Clin, 2014, 64(1):9-29.
  • 2Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node- negative tumors 1 cm or smaller[J]. J Clin Oncol, 2009, 27 (34~:5700-5706.
  • 3Parinyanitikul N, Lei X, Chavez-MacGregor M, et al. Re- ceptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival out- comes[J]. Clin Breast Cancer, 2015, 15(2):153-160.
  • 4Le Du F, Eckhardt BL, Lira B, et al. Is the future of person- alized therapy in triple-negative breast cancer based on molecular subtype[J].Oncotarget, 2015, 6(15): 12890-12908.
  • 5Gamucci T, Vaccaro A, Ciancola F, et al. Recurrence risk in small, node-negative, early breast cancer: a multicenter ret- rospective analysis[J]. J Cancer Res Clin Oncol, 2013, 139 (5): 853-860.
  • 6Gonzalez-Angulo AM, Akcakanat A, Liu S,et al. Open-la- bel randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer [J]. Ann Oncol, 2014, 25(6):1122-1127.
  • 7Vaz-Luis I, Ottesen RA, Hughes ME, et al. Outcomes by tu- mor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study[J]. J Clin Oncol, 2014, 32(20):2142-2150.
  • 8Colleoni M, Cole BF, Viale G, et al. Classical cyclophos- phamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast can- cer: resuhs from two randomized trials of adjuvant chemoen- docrine therapy for node-negative breast cancer[J]. J Clin Oncol, 2010, 28(18):2966-2973.
  • 9Cheang MC, Voduc KD, Tu D, et al. Responsiveness of in- trinsic subtypes to adjuvant anthracycline substitution in the NCIC. CTG MA.5 randomized trial[J]. Clin Cancer Res, 2012, 18(8):2402-2412.
  • 10Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubiein and Cyclophos- phamide: 7-Year Follow-Up of US Oneology Research Trial 9735[J]. J Clin Oncol, 2009, 27(8): 1177-1183.

二级参考文献37

  • 1杨丽平,杨永红.石榴皮的研究进展[J].云南中医中药杂志,2004,25(3):45-47. 被引量:88
  • 2赵扬帆,郑宝东.植物多酚类物质及其功能学研究进展[J].福建轻纺,2006(11):107-110. 被引量:85
  • 3徐珊,徐昌芬.肿瘤多药耐药性发生机制及中药逆转作用的研究进展[J].中国肿瘤生物治疗杂志,2006,13(6):404-411. 被引量:39
  • 4华晓东,巩媛媛,芮菁,唐元泰.黄芩素对皮肤过敏治疗作用的实验研究[J].天津中医药,2007,24(3):241-244. 被引量:30
  • 5Yamasaki M, Kitagawa T, Koyanagi N, et al. Dietary effect of pomegranate seed oil on immune function and lipid metabolism in mice[J]. Nutrition, 2006, 22(1): 54-59.
  • 6Kohno H, Suzuki R, Yasui Y, et al. Pomegranate seed oil rich in conjugated linolenic acid suppresses chemically in- duced colon carcinogenesis in rats[J]. Cancer Sci, 2004, 95 (6): 481-486.
  • 7Lansky EP, Jiang WQ, Mo H, et al. Possible synergistic pro statecancer suppression by anatomically discrete pomegran- ate fractions[J]. Investigational New Drugs, 2005, 23(1): 11-20.
  • 8Mehta R, Lansky EP. Breast cancer chemopreventive prop- erties of pomegranate (Punica granatum)fruit extracts in a mouse mammary organculture[J]. European Journal of Can- cer Prevention, 2004, 13(4): 345-348.
  • 9Kim ND, Mehta R, Yu W, et al. Chemopreventive and adju- vant therapeutic potential of pomegranate (Punica granatum) for human breast cancer[J]. Breast Cancer Research and Treatment, 2002, 71(3): 203-217.
  • 10Toi M, Bando H, Ramachandran C, et al. Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo[J]. Angiogenesis,2003, 6(2): 121-128.

共引文献8

同被引文献79

引证文献8

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部